Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

It came as AZ reported its third-quarter results, headlined by a 20% increase in revenues to $12.95 billion, which will be ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...

23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and ...

A £1 billion development aimed at creating a major centre for cancer research and treatment in South London has taken a step forwards with the selection of preferred bidders for the project.

Today, we live in an age of artificial intelligence (AI); more specifically, the age of generative AI (GenAI). In a recent report, 65% of respondents stated that their organisations are regularly ...

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage. Ben Hargreaves outlines how oncology is a priority for research, and how ...

Big data, artificial intelligence (AI), and machine learning (ML) are driving a technological revolution in healthcare. But with such rapid progress, understanding what these advancements mean in ...

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight. The companies reported mixed ...

Our round-up of financings in the biotech sector this week is led by BioAge Lab's filing of an initial public offering (IPO), with a placeholder target of $100 million, plus sizeable private ...

Indivior has secured a $111 million supply contract from the US federal government for its intranasal therapy for treating opioid overdose, in a further boost to the UK company’s fortunes.